Skip to main content
. 2018 May 17;42(2):799–810. doi: 10.3892/ijmm.2018.3686

Figure 6.

Figure 6

miR-137 suppresses cell viability of HTR-8/SVneo cells by decreasing PRKAA1 and upregulating IL-6. Following cell treatment with different concentrations of IL-6 (15.0, 30.0, 37.5 45.0 and 52.5 pg/ml), dorsomorphin (2.5, 5 and 10 µM) and AICAR (0.10, 0.25 and 0.50 mM) for 24 h, with untreated cells as a control group, the viability of HTR-8/SVneo cells was measured using a Cell Counting Kit assay. (A) Different concentrations of IL-6 suppressed the viability of HTR-8/SVneo cells. (B) PRKAA1 inhibitor (dorsomorphin) decreased the viability of HTR-8/SVneo cells. (C) PRKAA1 agonist (AICAR) increased the viability of HTR-8/SVneo cells. (D) Inhibition of viability induced by overexpression of miR-137 in HTR-8/SVneo cells was partly reversed by PRKAA1 agonist (AICAR, 0.5 mM). Data are presented as the mean ± standard error of the mean; statistical significance (P<0.05) was determined using Student's t-test or one-way analysis of variance followed Student-Newman-Keuls test, *P<0.05, **P<0.01, ***P<0.001. NS, no significant difference; miR-137, microRNA-137; PRKAA1 protein kinase AMP-activated catalytic subunit α1; IL-6, interleukin-6p; LV, lentiviral vector; NC, negative control.